Switch to aflibercept or ranibizumab after initial treatment with bevacizumab in eyes with neovascular AMD.

BMC Ophthalmol · 2017 · PMC5442868 · PMID 28535756

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

Although our results did not reach statistical significance, regarding the functional benefit we found aflibercept to be slightly more effective than ranibizumab.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.